Daiichi Sankyo submits Datroway sNDA in Japan for patients with metastatic triple negative breast cancer: Tokyo Friday, February 13, 2026, 11:00 Hrs [IST] Daiichi Sankyo has submi ...

Priority Review was granted by FDA for the first line metastatic TNBC treatment. Datroway significantly improved survival ...

Researchers have developed a new biomimetic nanocomposite (mPDA-Cas9) for treating triple-negative breast cancer (TNBC) by combining CRISPR/Cas9 gene ...

Japanese drugmaker Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labor and Welfare (MHLW) for Datroway (datopotamab deruxtecan) for the ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $878 million for the fourth quarter of 2025 and ...

On World Cancer Day 2026, medical experts are highlighting how early breast cancer care in India is becoming increasingly ...

The Cleveland Clinic is out with its findings on a vaccine to prevent breast cancer.

Phase 3 trial data show datopotamab deruxtecan reduces the risk of disease progression or death in patients with metastatic TNBC.

The landscape of triple-negative breast cancer (TNBC) is shifting rapidly. What was once a landscape dominated by standard cytotoxic chemotherapy is now a complex map of immunotherapy, PARP inhibitors ...

SRG-514 is designed to deliver immunotherapy intraoperatively, directly into the resection cavity during the time of tumor removal. The therapy aims to reprogram the local inflammatory response from ...

At Baylor Scott & White Health, a groundbreaking initiative is underway aiming to revolutionize early detection and intervention strategies for better breast cancer survivorship and beyond. Led by ...